

A digital survey to evaluate the self-perceived benefit of a SeS₂-1% salicylic acid shampoo in dermatologists with mild to-moderate scalp seborrheic dermatitis

Di Zong¹, Zhongxing Zhang¹, Stéphanie Leclerc-Mercier², Virginie Rasmont², Aihua Wei³

¹Active Cosmetics Division, L'Oréal China, Shanghai, China, ²Laboratoire Vichy International, Levallois-Perret, France, ³Department of Dermatology and Venerology, Beijing Tongren Hospital, Capital Medical University, Beijing China

INTRODUCTION

Seborrheic dermatitis (SD) is a chronic, relapsing inflammatory disorder affecting areas of the head and trunk where sebaceous glands are the most prominent and that evolves with flares and remission. SD is characterized by episodes of erythematous, scaly lesions of the scalp which can vary from mild to dense, diffuse, adherent flakes and pruritus. When mild scaling without visible inflammation is observed, SD is also named dandruff.¹

Topical products remain the mainstay of scalp seborrheic dermatitis (SSD) care. Selenium disulfide (SeS₂) is effective in managing both dandruff and SD. It reduces scales, itching, irritation and redness of the scalp. It has shown a full spectrum antimicrobial action against *Malassezia* yeasts and bacterial species.^{2,3}

To improve the adherence to use and thus to increase therapeutic benefit, a good user perception of treatment is important. Advocating the treatment benefit, based on a self-perceived use by health-care givers may thus be very helpful to convince users.

OBJECTIVE

To assess the perceived benefit of a SeS₂-1% salicylic acid shampoo in dermatologists with mild-to-moderate SSD.

MATERIAL AND METHODS

- Digital self-completed survey conducted in China in 100 dermatologists with mild-to-moderate SSD flaring or recurring after previous treatments.
- The SeS₂-1% salicylic acid shampoo was recommended to be applied 3 times per week for 4 weeks.
- Participants were asked to assess their SSD-related symptoms including flakes, scalp redness, itch as well as local tolerance and scalp and hair greasiness at baseline, Day 14 and Day 28 on a Visual analog scale (VAS) from 1=none to 10=very severe.
- Product qualities and overall satisfaction were assessed at Day 28. Tolerance was assessed throughout the study.

CONCLUSION

According to the dermatologists who used the product themselves, the SeS₂-1% salicylic acid shampoo used 3 times per weekly efficiently reduces symptoms of SSD after 4 weeks with a high user satisfaction, a good tolerance and a high willingness to recommend it.

RESULTS

- A total of 100 dermatologists participated and data from 95 were used for the statistical analysis.
- 75.0% were women; the mean age was 39.9±7.7 years. Overall, 28.4% had severe or very severe flakes, 47.4% moderate flakes and 24.3% had mild or almost no flakes and 25.0% had their SSD treated prior to this study.
- After 4 weeks of use of the SeS₂-based shampoo, only 3.2% still had severe or very severe flakes, 6.3% had moderate and 90.6% had mild or almost no flakes. Figure 1 provides a distribution of SSD scores at visit Day 0, Day 14 and Day 28
- Figure 2 shows the evolution over time of mean flake severity assessed on the VAS scale.

Figure 1 DISTRIBUTION OF SSD SEVERITY SCORES AT DAY 0, DAY 14 AND DAY 28






Figure 3a MEAN ERYTHEMA SEVERITY SCORE AT DAY 0, DAY 14 AND DAY 28




*p<0.01 compared to Day and between Day 28 and Day 14

Figure 3b MEAN PRURITUS SEVERITY SCORE AT DAY 0, DAY 14 AND DAY 28



*p<0.01 compared to Day and between Day 28 and Day 14


Figure 3c MEAN SCALP AND HAIR GREASINESS SEVERITY SCORE AT DAY 0, DAY 14 AND DAY 28



*p<0.01 compared to Day and between Day 28 and Day 14

- The evolution over time of the erythema, pruritus and scalp and hair greasiness score are given in Figure 3.
- Globally, 88.5% of the users were pleased with the product application, 86.3% reported that their multiple scalp symptoms and 80.0% that their hair quality had improved.
- The shampoo was considered by the users suitable as stand-alone product (87.4%) or as an adjuvant to pharmacological treatments (86.3%) with a highly attractive formulation (88.6%).
- 90.5% of the participants declared a high willingness to recommend the product.

Figure 2 THE MEAN FLAKE SEVERITY SCORE AT DAY 0, DAY 14 AND DAY 28



*p<0.01 compared to Day and between Day 28 and Day 14

References

1. Wikramanayake TC, Borda LJ, Miteva M, Paus R. Seborrheic dermatitis-Looking beyond *Malassezia*. *Exp Dermatol*. 2019;28(9):991-1001.
2. Sheth RA. A comparison of miconazole nitrate and selenium disulfide as anti-dandruff agents. *Int J Dermatol*. 1983;22(2):123-5.
3. Sauer GC. Treatment of seborrheic dermatitis («dandruff») with selenium sulfide suspension. *Mo Med*. 1952;49(11):911-2.

Funding

The study was funded by Laboratoires Vichy China.

Acknowledgments

The authors acknowledge the participation of the subjects, the writing support of Karl Patrick Göritz, SMWS France and the art work of Dominique Poisson, France.